| scholarly article | Q13442814 |
| P2093 | author name string | Reynolds GP | |
| Calcutt NA | |||
| Czudek C | |||
| Benton M | |||
| Godridge H | |||
| P2860 | cites work | The development of the pathologic changes of Alzheimer's disease and senile dementia in patients with Down's syndrome | Q35864823 |
| Increased concentrations and lateral asymmetry of amygdala dopamine in schizophrenia | Q41587309 | ||
| Serotonin nerve cells in Alzheimer's disease | Q41900986 | ||
| Biochemical Assessment of Serotonergic and Cholinergic Dysfunction and Cerebral Atrophy in Alzheimer's Disease | Q42453090 | ||
| Abnormalities of the nucleus basalis in Down's syndrome | Q42505608 | ||
| Neurochemical characteristics of early and late onset types of Alzheimer's disease | Q43051550 | ||
| Alzheimer-like brain monoamine deficits in adults with Down's syndrome | Q44006324 | ||
| Necropsy evidence of central cholinergic deficits in senile dementia | Q48319379 | ||
| Regional brain 5-hydroxytryptamine levels are reduced in senile Down's syndrome as in Alzheimer's disease | Q48355200 | ||
| Pathological evidence for neurotransmitter deficits in Down's syndrome of middle age. | Q48486372 | ||
| Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome | Q48516987 | ||
| Presenile dementia in Down's syndrome. Ultrastructural identity with Alzheimer's disease | Q48584854 | ||
| Changes of Biogenic Amines and Their Metabolites in Postmortem Brains from Patients with Alzheimer-Type Dementia | Q48641408 | ||
| Catecholamines and cholinergic enzymes in pre-senile and senile Alzheimer-type dementia and down's syndrome | Q48713477 | ||
| Plaques, tangles and dementia. A quantitative study | Q48874775 | ||
| Presenile dementia and Alzheimer's disease in mongolism | Q49059630 | ||
| Alzheimer-like cholinergic deficiency in Down syndrome | Q53196317 | ||
| Monoamine metabolism in Down syndrome | Q53196329 | ||
| Noradrenaline in Alzheimer-type dementia and Down syndrome | Q53794215 | ||
| Post-mortem distribution of dopamine and homovanillic acid in human brain, variations related to age, and a review of the literature | Q66895588 | ||
| Prevention and reversal of defective axonal transport and motor nerve conduction velocity in rats with experimental diabetes by treatment with the aldose reductase inhibitor Sorbinil | Q72733066 | ||
| Alzheimer's disease and Down's syndrome | Q72773681 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Alzheimer's disease | Q11081 |
| neurotransmitter | Q162657 | ||
| brain tissue | Q11850260 | ||
| P304 | page(s) | 775-778 | |
| P577 | publication date | 1987-06-01 | |
| P1433 | published in | Journal of Neurology, Neurosurgery and Psychiatry | Q1599804 |
| P1476 | title | Alzheimer-like neurotransmitter deficits in adult Down's syndrome brain tissue | |
| P478 | volume | 50 |
| Q34460504 | A biogenic amine-synapse mechanism for mental retardation and developmental disabilities |
| Q26798983 | A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome |
| Q33628428 | A pathological study of the association between Lewy body disease and Alzheimer's disease |
| Q48458709 | A unifying hypothesis of Alzheimer's disease. III. Risk factors |
| Q41184300 | Aging rather than aneuploidy affects monoamine neurotransmitters in brain regions of Down syndrome mouse models |
| Q42993144 | Amyloid precursor protein metabolism in fibroblasts from individuals with one, two or three copies of the amyloid precursor protein (APP) gene |
| Q48394916 | Brain vasopressin levels in Down syndrome and Alzheimer's disease |
| Q22252869 | Complementary and alternative therapies for Down syndrome |
| Q30459302 | Comprehensive behavioral phenotyping of Ts65Dn mouse model of Down syndrome: activation of β1-adrenergic receptor by xamoterol as a potential cognitive enhancer |
| Q38865366 | Dementia in Down's syndrome |
| Q48334770 | Detection of Lewy bodies in Trisomy 21 (Down's syndrome). |
| Q28343061 | Evidence for a membrane defect in Alzheimer disease brain |
| Q33589170 | Extrapyramidal features in advanced Down's syndrome: clinical evaluation and family history |
| Q37698148 | Glutamatergic transmission aberration: a major cause of behavioral deficits in a murine model of Down's syndrome. |
| Q49089225 | In vitro 1H and 31P NMR spectroscopic evidence of multiple aberrant biochemical pathways in murine trisomy 16 brain development |
| Q58365311 | Increased protein levels of serotonin transporter in frontal cortex of patients with Down syndrome |
| Q37912174 | Is it possible to improve neurodevelopmental abnormalities in Down syndrome? |
| Q33598454 | Lowering beta-amyloid levels rescues learning and memory in a Down syndrome mouse model |
| Q55003565 | Monoaminergic impairment in Down syndrome with Alzheimer's disease compared to early-onset Alzheimer's disease. |
| Q26863005 | Mouse models of Down syndrome as a tool to unravel the causes of mental disabilities |
| Q35208611 | Neonatal 192 IgG-saporin lesion of forebrain cholinergic neurons: focus on the life span? |
| Q22241936 | On the promise of pharmacotherapies targeted at cognitive and neurodegenerative components of Down syndrome |
| Q38004941 | Opioid system and Alzheimer's disease |
| Q48486732 | Personality and behaviour changes mark the early stages of Alzheimer's disease in adults with Down's syndrome: findings from a prospective population-based study |
| Q40623525 | Putative neurotransmitter abnormalities in infantile spasms: cerebrospinal fluid neurochemistry and drug effects |
| Q90400921 | RCAN1 Knockdown Reverts Defects in the Number of Calcium-Induced Exocytotic Events in a Cellular Model of Down Syndrome |
| Q58761442 | Rapamycin Treatment Ameliorates Age-Related Accumulation of Toxic Metabolic Intermediates in Brains of the Ts65Dn Mouse Model of Down Syndrome and Aging |
| Q48801795 | Similar deficits of central histaminergic system in patients with Down syndrome and Alzheimer disease |
| Q61979765 | Studien zur Verbesserung des Verständnisses von Lernschwierigkeiten bei Trisomie 21 – Bericht über die Ergebnisse einer Voruntersuchung |
| Q44658720 | Synaptic loss following depletion of noradrenaline and/or serotonin in the rat visual cortex: a quantitative electron microscopic study |
| Q36973492 | The place of choline acetyltransferase activity measurement in the "cholinergic hypothesis" of neurodegenerative diseases |
| Q52042219 | Treatment of functional decline in adults with Down syndrome using selective serotonin-reuptake inhibitor drugs. |
Search more.